Briumvi®

Understanding Briumvi® 

Briumvi® (ublituximab-xiiy) is a monoclonal antibody used to treat relapsing forms of multiple sclerosis (MS) in adults. It belongs to a class of anti-CD20 therapies that target and deplete B cells, which play a role in the immune system’s attack on the nervous system in MS. Briumvi® provides a convenient and effective option for patients requiring B-cell depleting therapy for relapsing MS, offering reduced infusion time to improve treatment efficiency and patient experience.

How Briumvi® Works:

• Targets and depletes CD20-positive B cells to reduce MS-related inflammation
• Prevents relapses and slows disease progression
• Offers a shorter infusion time for greater convenience

FDA Approval:

• Briumvi® (ublituximab-xiiy): Approved in December 2022

For more information, please visit the Briumvi® patient website and speak with your healthcare provider to determine if Briumvi® is the right treatment option for you.